ArticleJournal of comparative effectiveness research2024

Adverse event costs of systemic therapies for metastatic colorectal cancer previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy and biologics in the US.

Victoria Federico Paly et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.